Resumo

RAMOS PENAFIEL, Christian Omar et al. Effect of Metformin to a pretreatment with steroids in adult patients with acute lymphoblastic leukemia and in the viability of the MOLT-4 cell line. Medicas UIS [online]. 2015, vol.28, n.2, pp.221-228. ISSN 0121-0319.

Introduction: metformin, antidiabetic drug evaluated in several in vitro and in vivo cancer models, is able of increasing the adenosine monophosphate activated protein kinase and block tumor signaling pathways. Objetive: to evaluate the antitumor effects of metformin in MOLT-4 cell line and in patients under treatment for remission induction. Materials and methods: in vitro phase: essay in MOLT-4 cell line adding metformin 40 mM evaluating the viability and cell cycle by flow cytometry. Clinic phase: Case-control study in patients with de novo acute lymphoblastic leukemia, adding metformin three time a day on pretreatment stage and remission induction, against the historical record of the institutional protocol HGMLAL07. Statistical analysis: chi-square analysis, multivariate analysis for risk factors and evaluation of the effect over the remission by Odds ratio. Results: celular assay: metformina inhibited cell viability at 120 hours reducing the percentage of cells in phase S. Clinical assay: 151 patients were studied, 29.1% on metformina arm. The highest rate of good steroid response and complete remissions were found in patients who received metformin (59,1% versus 26,2% and 81,8% vs 57,9%) statistically significant (p= 0.000* and 0.006, 95% IC). Conclusions: the addition of metformin to chemotherapy increased the good steroids response to steroids and rates of complete remissions. In vitro, and similar to other models, metformin arrest cells in G₀/G₁, inducing a decrease in cell viability. MÉD.UIS. 2015;28(5):221-8

Palavras-chave : Precursor Cell Lymphoblastic Leukemia-Lymphoma; Metformin; Steroids.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )